The anti-tumor effects of hAMSCs on LNCaP prostate cancer cells through induction of apoptosis, suppression of epithelial-mesenchymal transition process, and downregulation of EGFR were shown (Safari et al., 2021). The gene discussed is EGFR; the disease is prostate carcinoma.